Douglas Pharmaceutical's Chief Scientific Officer talks about a new drug for treatment resistant depression
In this interview on Newstalk ZB, Douglas Pharmaceutical’s Chief Scientific Officer, Dr Peter Surman, talks about a new ketamine based drug which has been developed by Douglas. Early results from clinical trials are showing this novel medication is proving highly successful in supporting people experiencing serious, treatment resistant depression. Some patients on the trial have reported significant mood changes within 24 hours of taking the drug. Others have said it is the first time they have felt ‘normal’ in over 20 years of suffering from severe depression.
Listen to the full interview